Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

INVO Fertility, Inc. Common Stock

IVF

INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. It is offering the intravaginal culture (IVC) procedure enabled by INVOcell medical device (INVOcell). The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The company's segments include: The Clinics Services operating segment consisting of financial information for WFI and the Atlanta Clinic and The INVOcell Device operating segment consisting of financial information relating to the manufacture and sales of the INVOcell.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $2.20 – $2.38
Volume 46,020
Market cap $3M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.86M
Price / earnings
—
Price / book
0.17×
Price / sales
0.38×
EV / sales
0.1×
EV / EBITDA
-0.14×

Profitability

Earnings per share
-$5.95
Return on assets
-27.45%
Return on equity
-43.01%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.1×
Current ratio
0.71×
Quick ratio
0.67×
Cash ratio
0.57×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$4.81M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IVF, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025
Revenue$2.18M$2.02M$1.58M$1.76M$1.86M
Cost of revenue$1.41M$1.29M$1.05M$1.13M$1.09M
Gross profit$762.67K$727.83K$536.86K$629.35K$770.05K
Selling, general and administrative$1.91M$2.18M$1.81M$2.13M$2.19M
Research and development$0$0$0$0$0
Total operating expenses$2.05M$2.32M$1.95M$2.26M$3.76M
Operating income-$1.29M-$1.59M-$1.41M-$1.64M-$2.99M
Interest expense-$177.23K-$180.32K-$627.11K-$145.8K-$440.6K
Income before taxes$944.89K-$5.54M$1.86M-$2.64M-$1.54M
Income taxes$56.15K$0-$150.37K$0$0
Net income$888.74K-$5.54M$2.01M-$2.64M-$3.62M
Net income attributable to common shareholders$888.74K-$5.54M$202.85K-$2.64M-$3.62M
EBITDA-$1.14M-$1.45M-$1.28M-$1.5M-$1.42M
Basic earnings per share$1.68-$13.52$2.21-$123.20-$1,456.92
Diluted earnings per share$1.40-$13.52$2.21-$123.20-$1,456.92

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

INVO Fertility Announces a 1:4 Reverse Stock Split Effective Pre-Market Opening on October 30, 2026

INVO Fertility announced a 1-for-4 reverse stock split effective October 30, 2026, under the same ticker symbol 'IVF' on Nasdaq Capital Market. Post-split, the company will have approximately 1,192,841 shares outstanding and 62,500,000 authorized shares. The company operates four fertility clinics in the U.S. and distributes its proprietary INVOcell technology to third-party clinics.

Benzinga

INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic "Family Beginnings"

INVO Fertility (NASDAQ: IVF) has successfully closed its acquisition of Family Beginnings, an Indiana-based fertility clinic, for $760,000 in cash and preferred stock. The clinic generated approximately $1 million in revenue and $0.2 million in net income for the 9 months ended September 30, 2025. The acquisition expands INVO's geographic footprint and aligns with its strategy to increase access to high-quality fertility care while maintaining the clinic's existing medical leadership under Dr. James Donahue.

Benzinga

Why INVO Fertility (IVF) Stock Is Trending Overnight

INVO Fertility (NASDAQ:IVF) shares fell 14.78% to $2.02 in after-hours trading on Tuesday, despite closing the regular session up 191.73% at $2.37. The company signed a definitive agreement to acquire Family Beginnings fertility clinic for $750,000 and reported Q3 2025 revenue growth of 23% year-over-year to $1.76 million. However, the company posted a net loss of $2.6 million, and the stock has declined 98.25% over the past 12 months, trading near its 52-week low.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 30, 20261-for-4reverse split
Mar 27, 20261-for-5reverse split
Nov 28, 20251-for-8reverse split
Jul 21, 20251-for-3reverse split